Biotech in Phase 1 trials. Technology expands cancer stem cells to provide diagnostic of best personalized therapy. Product launch in 2015.
Cordgenics is a clinical stage (Phase l) biotech with proprietary technology (patents applied for) that will provide cancer patients with a personalized diagnostic as to which chemotherapy agents (or "cocktail") will kill the progenitor "stem" cells that cause cancer to return. Unlike other approaches, cells replicated by the Co. are identical to the originals w/o using harmful growth factors. We expect to launch a commercial product in 2015.